Product logins

Find logins to all Clarivate products below.


Psoriasis | Treatment Algorithms: Claims Data Analysis | Palmoplantar Pustular Psoriasis / Generalized Pustular Psoriasis | US | 2019

Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP]) or are localized, typically on the hands and feet (palmoplantar pustular psoriasis [PPP]). Despite being more severe than general plaque psoriasis and potentially life-threatening, no drugs have been well studied for this psoriasis subtype and none are specifically indicated for PPP / GPP. Treatment typically includes topical corticosteroids, methotrexate, retinoids, and phototherapy. However, biologics, including TNF-alpha inhibitors and IL-17 inhibitors, and targeted orals used for plaque psoriasis are also increasingly being used to treat PPP / GPP.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PPP / GPP patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PPP / GPP patients?
  • How have TNF-alpha inhibitors been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of PPP / GPP patients receive drug therapy within one year of diagnosis, and how quickly do they receive it? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of PPP / GPP patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Report
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
Report
Psoriasis – Access & Reimbursement – Access & Reimbursement – Psoriasis (US)
The U.S. psoriasis treatment landscape is rapidly evolving, with newer, more effective therapies increasing competition for favorable MCO coverage, further intensified by the introduction of…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting…
Report
GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…